JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics (CRNX) to $52 from $53 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect slightly higher spending assumptions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics management to meet with Cantor Fitzgerald
- Crinetics receives Orphan Drug designation for atumelnant in CAH
- Crinetics’ treatment of CAH granted FDA orphan designation
- Crinetics Pharma’s Earnings Call: Progress Amid Challenges
- Crinetics Pharmaceuticals: A Promising Buy with Strategic Initiatives and Upcoming Milestones